先天性黑色素细胞痣核心结局域集开发方案(OCOMEN项目)
先天性黑色素细胞痣(CMN)缺乏国际公认的结局域共识,影响治疗比较与患者沟通。OCOMEN项目遵循COMET与CS-COUSIN推荐,通过系统综述、焦点小组、e-Delphi调查和共识会议开发核心结局集(COS),供临床研究与随访使用。
要点
- 大型CMN带来心理社会负担,并有黑色素瘤或神经皮肤黑变病风险。
- 项目采用系统综述、焦点小组、e-Delphi和共识会议五步法开发COS。
- COS拟用于CMN患者随访、临床研究和实践,促进结局标准化。
核心结论
- OCOMEN项目旨在开发先天性黑色素细胞痣的核心结局集(COS),以统一临床 trials 中应测量和报告的结局。
研究设计与样本
- 项目遵循COMET和CS-COUSIN推荐,包括系统综述、焦点小组、结局分类、e-Delphi调查和在线共识会议五个步骤。
主要发现
- 原文未报告研究结果,仅描述项目方案与预期传播方式。
关键数值与推荐
- 核心结局集(COS)定义为特定健康状况所有临床试验中推荐测量和报告的最小结局集合。
临床怎么用
- COS可用于CMN患者(无论是否治疗)的随访、临床研究和实践,便于比较治疗选项和制定治疗政策。
局限性
- 本文为方案报告,尚未产生共识结局域,实际应用需待项目完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Having large congenital melanocytic naevi (CMN) is associated with a psychosocial burden on patients and their parents because of its remarkable appearance and the extra care it may require. Large CMN also pose an increased risk of malignant melanoma or neurocutaneous melanosis. There is a lack of international consensus on what important outcome domains to measure in relation to treatment. This makes it difficult to compare options, to properly inform patients and their parents, and to set up treatment policy for CMN. Therefore, we aim to develop a core outcome set (COS), i.e. the minimum set of outcomes that are recommended to be measured and reported in all clinical trials of a specific health condition. This COS can be used in the follow-up of CMN patients with or without treatment, in clinical research and practice. METHODS: In the Outcomes for Congenital Melanocytic Nevi (OCOMEN) projects, we follow the recommendations from the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the Cochrane Skin Core Outcomes Set Initiative (CS-COUSIN). This project entails the following: (i) a systematic review to identify the previous reported outcomes in literature; (ii) focus groups with national and international patients and parents to identify patient-important outcomes; (iii) classification of outcomes into outcome domains; (iv) e-Delphi surveys in which stakeholders (patients/parents and professionals) can rate the importance of domains and outcomes; and (v) an online consensus meeting to finalize the core outcome domains of the COS. RESULTS: The results will be disseminated by means of publication in a leading journal and presentations in international meetings or conferences. We engage international experts in CMN, both patients and professionals, to ensure the international utility and applicability of the COS.
引用
- Oei W, Fledderus AC, Korfage I, et al. Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project). J Eur Acad Dermatol Venereol. 2019. PMID: 31419337. doi:10.1111/jdv.15874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。